NCT06846073View on ClinicalTrials.gov

Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.

NAActive, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Diabetic Macular Edema (DME)
Interventions
COMBINATION_PRODUCT

The combination of intravitreal anti-VEGF and dexamethasone implants injections.

Early combination of intravitreal dexamethasone implant and anti-VEGF injection for the treatment of DME.

Trial Locations (1)

310000

Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Ningbo Eye Hospital

OTHER

collaborator

Jiaxing Hospital of T.C.M

UNKNOWN

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06846073 - Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME. | Biotech Hunter | Biotech Hunter